Optimization and Validation of a Stability-Indicating RP-HPLC Method for Determination of Azithromycin and Its Related Compounds

被引:0
作者
El-Gindy, Alaa [1 ]
Attia, Khalid A. [2 ]
Nassar, Mohammad Wafaa [2 ]
Al Abasawi, Nasr M. [2 ]
Al-Shabrawi, Maisra [3 ]
机构
[1] Suez Canal Univ, Fac Pharm, Dept Pharmaceut Analyt Chem, Ismailia 41522, Egypt
[2] Al Azhar Univ, Fac Pharm, Dept Pharmaceut Analyt Chem, Cairo, Egypt
[3] Gulf Pharmaceut Ind JULPHAR, Qual Control Dept, Ras Al Khaymah, U Arab Emirates
关键词
LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY; MASS-SPECTROMETRY; HUMAN PLASMA; PHARMACEUTICAL FORMULATIONS; QUANTITATIVE-DETERMINATION; ELECTROCHEMICAL DETECTION; UV DETECTION; ASSAY; QUANTIFICATION; TABLETS;
D O I
暂无
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A validated stability-indicating HPLC method was developed for the analysis of azithromycin (AZ) and its related compounds in raw materials, capsule, and suspension using an Xterra RP C18 column at 50 degrees C with UV detection at 215 nm. Isocratic elution was employed using the mobile phase 14 mM disodium hydrogen phosphate (pH 10.5, adjusted by 1 M NaOH) methanol acetonitrile tetrahydrofuran (40.0 + 30.0 + 30.0 + 0.1, v/v/v/v). AZ and 14 of its related compounds were separated and quantified. The described method was linear over the range of 2-1800 mu g/mL AZ with (r = 0.9999). The stability of AZ was studied under accelerated acidic, alkaline, and oxidative conditions. The proposed method was used to investigate the kinetics of acidic and alkaline hydrolysis process of AZ at different temperatures, and the apparent pseudo first-order rate constant, half-life, and activation energy were calculated. The major peak detected from the degradation of AZ in alkaline and acidic conditions was decladinosylazithromycine, while azithromycin N-oxide was detected from the oxidative degradation. Long-term stability studies for capsule and oral suspension were carried out. The proposed stability-indicating method was completely validated according to the U.S. Food and Drug Administration requirements.
引用
收藏
页码:513 / 522
页数:10
相关论文
共 33 条
[11]  
2-5
[12]  
INOV TT, 1998, J PHARM BIOMED ANAL, V17, P903
[13]   NEW DIRECTIONS FOR MACROLIDE ANTIBIOTICS - PHARMACOKINETICS AND CLINICAL EFFICACY [J].
KIRST, HA ;
SIDES, GD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (09) :1419-1422
[14]   REVERSED-PHASE HPLC ANALYSIS OF THE SEMISYNTHETIC MACROLIDE ANTIBIOTIC AZITHROMYCIN [J].
KOVACICBOSNJAK, N ;
MARINCEL, J ;
LOPOTAR, N ;
KOBREHEL, G .
CHROMATOGRAPHIA, 1988, 25 (11) :999-1003
[15]  
KRULL IS, 2001, LCGC, V29, P604
[16]   Development and validation of a micellar liquid chromatographic method with UV detection for determination of azithromycin in tablets and capsules [J].
Kulikov, AU ;
Verushkin, AG .
CHROMATOGRAPHIA, 2004, 60 (1-2) :33-38
[17]   TLC-densitometric determination of azithromycin in pharmaceutical preparations [J].
Kwiecien, Anna ;
Krzek, Jan ;
Biniek, Lukasz .
JPC-JOURNAL OF PLANAR CHROMATOGRAPHY-MODERN TLC, 2008, 21 (03) :177-181
[18]  
Lakshmi sivasubramanian., 2004, Indian J Pharm sci, P249
[19]   Sensitive liquid chromatography/mass spectrometry assay for the quantification of azithromycin in human plasma [J].
Liu, Fei ;
Xu, Yu ;
Huang, Jinchang ;
Gao, Shu ;
Guo, Qingxiang .
BIOMEDICAL CHROMATOGRAPHY, 2007, 21 (12) :1272-1278
[20]   LC determination of impurities in azithromycin tablets [J].
Miguel, L ;
Barbas, C .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2003, 33 (02) :211-217